“An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Improves Quality of Life in Psoriasis: Results from a Phase 2 Study”. SKIN The Journal of Cutaneous Medicine, vol. 3, Nov. 2019, p. S12, https://doi.org/10.25251/skin.3.supp.12.